共查询到20条相似文献,搜索用时 15 毫秒
1.
目的获取人钠/碘同向转运体(hNIS)基因cDNA,研究其转导黑色素瘤细胞在体外和体内能否介导放射性碘摄取,从而探索该策略用于黑色素瘤放射性碘治疗的可能性.方法运用逆转录聚合酶链反应从人甲状腺组织总RNA中扩增出hNIS基因cDNA,将其克隆至真核载体pc-DNA3中,电转化法分别将重组质粒pc-DNA3-hNIS及空质粒pc-DNA3转导黑色素瘤细胞(B16),分别建立了细胞系B16-A和B16-B.在体外培养条件下检测其对放射性碘的摄取及外流情况.继而将三种细胞系接种C57小鼠行131I显像和肿瘤摄取125I动态定量测定.结果成功克隆到hNIS基因,并建立了能稳定表达hNIS的新型细胞系B16-A.B16-A细胞的摄碘能力较B16细胞高17倍,较B16-B细胞高19倍.碘的外流过程迅速,T1/2eff仅10 min.体内实验发现B16-A细胞所形成肿瘤能摄取放射性碘,腹腔注射125I后1、2、4、12、24 h肿瘤组织的%ID/g平均为12.22.10.91、8.73、1.24、0.19,125I在肿瘤组织内的生物半衰期约为6 h.B16-A细胞系所成肿瘤摄碘量与对照组相比较,P<0.01,差别具有高度统计意义.结论hNIS基因转导黑色素瘤细胞足以介导放射性碘摄取,但有效半衰期较短,难以产生足够的治疗剂量,有必要进一步研究如何增加放射性碘的摄取量及延长碘在细胞内的滞留时间以提高其放射生物学效应. 相似文献
2.
目的本实验通过三种细胞因子(肿瘤坏死因子-α,干扰素-γ和白细胞介素-6)对乳腺细胞钠碘转运体(NIS)基因表达的影响,探讨乳腺肿瘤组织NIS的表达特点和调控因素.方法采用乳腺癌细胞MCF-7和MB453进行培养,分别给予不同浓度的肿瘤坏死因子-α,干扰素-γ或白细胞介素-6刺激72 h.采用RT-PCR方法检测细胞中NIS mRNA表达情况.结果乳腺癌细胞在经过肿瘤坏死因子-α,干扰素-γ或白细胞介素-6刺激后,细胞中NIS的mRNA表达比对照组明显降低,并且与细胞因子浓度呈负相关.结论肿瘤坏死因子-α,干扰素-γ和白细胞介素-6对乳腺癌细胞MCF-7和MB453的NIS基因mRNA表达有抑制作用,这提示细胞因子可能通过调节乳腺癌NIS基因mRNA的表达,从而影响乳腺癌细胞对放射性碘治疗的敏感性. 相似文献
3.
We evaluated the potential of radioiodide therapy in human sodium iodide symporter (hNIS)-defective thyroid cancer cells via exogenous hNIS expression. Three human thyroid cancer cells (ARO, FRO and NPA) of different origin were transduced by a recombinant adenovirus encoding hNIS expression cassette (Rad-hNIS). The cells were efficiently transduced by a recombinant adenovirus in a virus dose-dependent manner. Consequently, the hNIS protein could be readily detected by Western blot analysis 48-h post-infection at 10 infectious virus particles per cell. These hNIS-transduced cells actively transported iodide into the cytoplasm at the level of 11635.3, 61571.6, and 19367.5 pmoles/10(6) cells in ARO, FRO, and NPA, respectively. However, a significant amount of iodide was eluted to an iodide-free media within 60 min in all the cell lines. RT-PCR analysis revealed that the expression of genes related to iodide trapping (Tg, TSHR and TPO) was dramatically downregulated in these cells. The present study indicates that functional hNIS can be efficiently expressed and is responsible for active transport of iodide in hNIS-negative human thyroid cancer cells by a recombinant adenovirus. However, the human thyroid cancer cells, along with downregulation of iodide metabolism-related gene expression, lose the ability to maintain iodide. Therefore, these kinetic characteristics of iodide uptake and efflux may limit the therapeutic potential of hNIS/radioiodide-based treatment following exogenous hNIS expression in human thyroid cancer. 相似文献
4.
5.
Boelaert K Smith VE Stratford AL Kogai T Tannahill LA Watkinson JC Eggo MC Franklyn JA McCabe CJ 《Oncogene》2007,26(30):4344-4356
The ability of the thyroid to accumulate iodide provides the basis for radioiodine ablation of differentiated thyroid cancers and their metastases. Most thyroid tumours exhibit reduced iodide uptake, although the mechanisms accounting for this remain poorly understood. Pituitary tumour transforming gene (PTTG) is a proto-oncogene implicated in the pathogenesis of thyroid tumours. We now show that PTTG and its binding factor PBF repress expression of sodium iodide symporter (NIS) messenger RNA (mRNA), and inhibit iodide uptake. This process is mediated at least in part through fibroblast growth factor-2. In detailed studies of the NIS promoter in rat FRTL-5 cells, PTTG and PBF demonstrated specific inhibition of promoter activity via the human upstream enhancer element (hNUE). Within this approximately 1 kb element, a complex PAX8-upstream stimulating factor 1 (USF1) response element proved critical both to basal promoter activity and to PTTG and PBF repression of NIS. In particular, repression by PTTG was contingent upon the USF1, but not the PAX8, site. Finally, in human primary thyroid cells, PTTG and PBF similarly repressed the NIS promoter via hNUE. Taken together, our data suggest that the reported overexpression of PTTG and PBF in differentiated thyroid cancer has profound implications for activity of the NIS gene, and hence significantly impacts upon the efficacy of radioiodine treatment. 相似文献
6.
Corinne Renier Hannes Vogel Onyinye Offor Chen Yao Irene Wapnir 《Journal of neuro-oncology》2010,96(3):331-336
Breast cancer brain metastases are on the rise and their treatment is hampered by the limited entry and efficacy of anticancer
drugs in this sanctuary. The sodium iodide symporter, NIS, actively transports iodide across the plasma membrane and is exploited
clinically to deliver radioactive iodide into cells. As in thyroid cancers, NIS is expressed in many breast cancers including
primary and metastatic tumors. In this study NIS expression was analyzed for the first time in 28 cases of breast cancer brain
metastases using a polyclonal anti-NIS antibody directed against the terminal C-peptide of human NIS gene and immunohistochemical
methods. Twenty-five tumors (84%) in this retrospective series were estrogen/progesterone receptor-negative and 15 (53.6%)
were HER2+. Overall 21 (75%) cases and 80% of HER2 positive metastases were NIS positive. While the predominant pattern of
NIS immunoreactivity is intracellular, plasma membrane immunopositivity was detected at least focally in 23.8% of NIS-positive
samples. Altogether, these findings indicate that NIS expression is prevalent in breast cancer brain metastases and could
have a therapeutic role via the delivery of radioactive iodide and selective ablation of tumor cells. 相似文献
7.
W. Chai X. Yin L. Ren M. Cai T. Long M. Zhou Y. Tang N. Yang S. Hu 《Clinical & translational oncology》2015,17(10):795-802
The sodium/iodide symporter (NIS) is involved in iodide uptake and has been used for the diagnosis and treatment of thyroid cancer. Transfection of the NIS gene in A549 human lung cancer cells can induce radioactive iodine (131I) and radioactive technetium (99mTc) uptake. The aim of the present study was to assess the role of NIS in 99mTc and 131I uptake by the A549/DDP human cisplatin-resistant lung cancer cell line. To do so, recombinant adenovirus, adenovirus-enhanced green fluorescent protein-human NIS (Ad-eGFP-hNIS) and Ad-eGFP-rat NIS (Ad-eGFP-rNIS) vectors were established. These vectors were transfected into A549/DDP cells and xenograft tumors in nude mice. Assessment of 99mTc and 131I uptake was performed. Results showed that the transfection efficiency of Ad-eGFP-hNIS and Ad-eGFP-rNIS in A549/DDP cells was at least 90 % in all experiments, and that the uptake ability of 99mTc and 131I was highly enhanced (14–18 folds for 99mTc, and 12–16 folds for 131I). However, the radionuclide concentration in transfected NIS genes’ A549/DDP cells reached a plateau within 30–60 min, indicating that NIS transport led rapidly to 99mTc and 131I saturation in cells. In xenograft tumor models, uptake of 99mTcO4 ? was obviously higher in the hNIS and rNIS groups compared with controls. In conclusion, these results support the hypothesis that A549/DDP cells can effectively uptake 99mTc and 131I when transfected with the hNIS and rNIS gene. The rNIS or hNIS gene could be used as an effective method for the effective delivery of radioactive products to specific tissues for imagery and/or treatment. 相似文献
8.
Montiel-Equihua CA Martín-Duque P de la Vieja A Quintanilla M Burnet J Vassaux G Lemoine NR 《Cancer gene therapy》2008,15(7):465-473
Expression of the sodium iodide symporter (hNIS) has been detected in breast cancer tissue, but frequently, not at the levels necessary to mediate (131)I accumulation. Transducing the hNIS gene into breast cancer cells with adenovirus could be a tractable strategy to render breast cancer susceptible to radioiodide therapy. We constructed the replication-incompetent virus, AdSERE, in which an estrogen-responsive promoter directs the expression of hNIS. In vitro, we demonstrate that AdSERE mediates hNIS expression and iodide uptake in ER+ breast cancer cells. In vivo, we show that AdSERE-infected ER+ tumors can be imaged due to tracer accumulation; in addition, AdSERE in combination with therapeutic doses of (131)I suppresses tumor growth. 相似文献
9.
目的:探讨甲状腺乳头状癌(PTC)患者中BRAFV600E基因突变及钠碘同向转运体(NIS)蛋白的表达及两者间的相关性.方法:收集2008-01-01—2011-01-01青岛大学医学院附属医院病理科PTC石蜡包埋组织30例,其中癌旁组织为正常组织(G正常组)15例,癌旁组织为结节性甲状腺肿组织(G结甲组)15例.对PTC组织行DNA提取、PCR扩增、基因测序检测BRAFV600E基因突变,同时采用免疫组化的方法分析NIS蛋白表达,结果以免疫组化评分(IHS)表示.结果:30例PTC均无BRAFV600E基因突变;30例PTC组织中NIS蛋白表达,从0~12分,G正常组IHS=(7.92±3.01)分,G结甲组IHS=(6.58±2.71)分,两组NIS差异无统计学1意义,t=1.11,P=0.95;BRAFV600E突变与NIS蛋白表达无相关性.结论:尚未发现癌旁不同的PTCBRAFV600E基因有突变及NIS蛋白表达的差异.BRAFV600E基因突变与NIS表达在PTC中的关系有待进一步研究. 相似文献
10.
11.
12.
Yu Yan Hongfei Zhang Yudong Zhang Xiaotan Wang 《中国肿瘤临床(英文版)》2008,5(1):30-34
OBJECTIVE To examine the possibility of human sodium iodide symporter (hNIS) protein expression in lung cancer cells. METHODS Human lung A549 cancer cells were thawed and cultured in vitro. The cells were divided into an experimental group transfected with a recombinant pcDNA3-hNIS plasmid and a control group transfected only with a pcDNA3 plasmid. The recombinant plasmid vector encoding the hNIS gene (pcDNA3-hNIS) was amplified, purified and identified. The hNIS gene was followed by DNA sequencing. A Western blot and an immunohistochemical assay were applied to detect the hNIS protein expression in the transfected human lung A549 cancer cells. RESULTS Restriction enzyme digestion and DNA sequencing results showed the size and direction of the inserted gene in the recombinant pcD- NA3-hNIS plasmid was correct. The Western blot method and immunohistochemical analysis showed a positive NIS protein expression in the experimental group. The NIS protein was detected mainly in the cell membranes showing a positive rate up to 70.6% with no expression of the NIS protein in the control group. There was a significant difference between two groups (P=0.000). CONCLUSION The hNIS gene was transfected effectively into human lung A549 cancer cells mediated by Lipofectamine 2000, and was expressed with its protein in vitro. 相似文献
13.
目的:探讨钠/碘转运体(sodium iodide symporter,NIS)在甲状腺癌组织中的表达.方法:应用实时荧光定量PCR(real-time fluorescence quantitative-PCR, RFQ-PCR)和免疫组织化学法检测NIS mRNA和蛋白在18例正常甲状腺组织、27例结节性甲状腺肿组织和23例甲状腺癌组织中的表达.结果: 甲状腺癌组织中NIS mRNA的表达显著低于正常甲状腺组织和结节性甲状腺肿组织(P=0.002).免疫组织化学检测结果表明,甲状腺癌组织中NIS蛋白主要定位于细胞质,强阳性表达13例(56.6%)、阳性表达3例(13.0%),强阳性表达率显著高于正常甲状腺组织(P=0.010).与正常甲状腺组织相比,甲状腺癌组织中NIS mRNA表达下降并且NIS蛋白表达升高者17例(74%),显著高于结节性甲状腺肿组织(χ2=4.428,P=0.035).结论:甲状腺癌组织中NIS mRNA的表达下降而NIS蛋白的表达增强,推测NIS蛋白主要位于细胞质可能是NIS不能发挥正常的运输功能,导致甲状腺癌患者不能聚碘的重要原因之一. 相似文献
14.
J.-D. Lin E. C. Chan T. C. Chao K. T. Chen C. Hsueh Y. S. Ho H. F. Weng 《Annals of oncology》2000,11(5):625-629
Active iodide uptake across the basal membrane mediated by human sodiumiodide symporter (hNIS) has been shown to be a process coupled with the flowof sodium. There is still controversy as to the amount of hNIS expressionpresent in different kinds of human thyroid cancer tissues. In this study, wepresent a 58-year-old women with follicular thyroid carcinoma with vertebraand skull metastases. 201Tl and 5 mCi 131I scans clearlydemonstrated the metastatic lesions in the brain of this patient. Thyroid andmetastatic tissues were then obtained for this study, which is aimed atcomparing the iodide trapping ability in vivo and in vitro of hNIS, and then comparing their expression in both thyroid tissue andmetastatic tissues. Polyclonal antibodies to hNIS and competitive RT–PCRwere used to analyze the symporter protein and mRNA expressed in follicularhuman thyroid and metastatic tissues. Positive staining of the symporterprotein was performed in the follicular thyroid carcinomas, otherwise, themetastatic tissues could not have demonstrated the protein in the staining.Follicular thyroid carcinoma tissues from thyroid were revealed around 5 pghNIS expressed in follicular thyroid carcinoma tissues from the thyroid.Otherwise, there was almost an absence of hNIS expression in the metastatictissue. These discrepancies of the expression in hNIS in vivo and in vitrostudies need further investigation. 相似文献
15.
Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats 总被引:6,自引:0,他引:6
Faivre J Clerc J Gérolami R Hervé J Longuet M Liu B Roux J Moal F Perricaudet M Bréchot C 《Cancer research》2004,64(21):8045-8051
Radioiodine therapy of nonthyroid cancers after sodium iodide symporter (NIS) gene delivery has been proposed as a potential application of gene therapy. However, it seems to be precluded by the rapid efflux of taken up iodine from most transduced xenografted tumors. We present an in vivo kinetic study of NIS-related hepatic iodine uptake in an aggressive model of hepatocarcinoma induced by diethylnitrosamine in immunocompetent Wistar rats. We followed the whole-body iodine distribution by repeated imaging of live animals. We constructed a rat NIS (rNIS) adenoviral vector, Ad-CMV-rNIS, using the cytomegalovirus (CMV) as a promoter. Injected in the portal vein in 5 healthy and 25 hepatocarcinoma-bearing rats and liver tumors in 9 hepatocarcinoma-bearing rats, Ad-CMV-rNIS drove expression of a functional NIS protein by hepatocytes and allowed marked (from 20 to 30% of the injected dose) and sustained (>11 days) iodine uptake. This contrasts with the massive iodine efflux found in vitro in human hepatic tumor cell lines. In vivo specific inhibition of NIS by sodium perchlorate led to a rapid iodine efflux from the liver, indicating that the sustained uptake was not attributable to an active retention mechanism but to permanent recycling of the effluent radioiodine via the high hepatic blood flow. Radioiodine therapy after Ad-CMV-rNIS administration achieved a strong inhibition of tumor growth, the complete regression of small nodules, and prolonged survival of hepatocarcinoma-bearing rats. This demonstrates for the first time the efficacy of NIS-based radiotherapy in a relevant preclinical model of nonthyroid human carcinogenesis. 相似文献
16.
17.
18.
Effect of ligands of nuclear hormone receptors on sodium/iodide symporter expression and activity in breast cancer cells 总被引:2,自引:0,他引:2
Tanosaki S Ikezoe T Heaney A Said JW Dan K Akashi M Koeffler HP 《Breast cancer research and treatment》2003,79(3):335-345
Iodide uptake by normal and cancerous thyroid cells is an active process mediated by the sodium/iodide symporter (NIS). Using quantitative real-time RT-PCR, we found that all 22 fresh human breast cancer samples had very low NIS expression similar to levels in untreated MCF-7 breast cancer cells. 9-cis retinoic acid (9-cis RA), a ligand for both retinoic acid receptor (RAR)/retinoic X receptor (RXR) heterodimers as well as RXR/RXR homodimers, markedly induced NIS mRNA expression in MCF-7 breast cancer cells in a dose- and time-dependent fashion, with maximal levels occurring at 12 h. All-trans retinoic acid, ATRA, a RAR specific ligand had a similar potency. Among eight breast cancer cell lines, three out of four estrogen receptor (ER)-positive and zero of four ER-negative cell lines responded to 9-cis RA by increasing their expression of NIS. Combining a RAR with a RXR selective ligand enhanced both NIS mRNA expression and iodide uptake in MCF-7 cells. Similarly, a ligand for proliferator-activated receptor (PPAR) when combined with 9-cis RA synergistically increased both NIS mRNA levels and iodide uptake in these MCF-7 cells. The iodide uptake was blocked by KClO4. In conclusions, these findings suggest that selected combinations of NHR ligands should be examined in a limited trial to determine if their administration to patients allows the use of radioactive iodine for diagnosis and possibly treatment of metastatic breast cancer. 相似文献
19.
20.
目的:探讨全反式维甲酸(ATRA)对甲状腺癌细胞株钠/碘同向转运体(NIS)基因表达、吸碘能力的影响,为ATRA用于放射性碘治疗甲状腺癌提供理论依据。方法:分别以不同浓度(10^-7mol/L、10^-6mol/L、10^-5mol/L、10^-4mol/L)的ATRA处理体外培养的甲状腺癌细胞株(FTC-133),48h后利用半定量RT-PCR检测细胞NISmRNA表达,γ-计数仪检测细胞吸碘能力。结果:ARTA浓度在(0~10%-5)mol/L范围内,细胞NIS基因表达及吸碘能力随ARTA剂量的增加而增加(P〈0.05)。当ARTA浓度达10%-4mol/L时,增加与前一浓度相比无统计学意义(P〉0.05)。结论:ATRA可上调甲状腺癌FTC-133细胞NIS基因表达,增强其吸碘能力,而且这种作用在一定浓度范围内具有剂量依赖性。 相似文献